🇺🇸 5-alpha reductase inhibitor in United States

10 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bladder Cancer — 1 report (10%)
  2. Dysuria — 1 report (10%)
  3. Erectile Dysfunction — 1 report (10%)
  4. Haemoglobin Decreased — 1 report (10%)
  5. Libido Decreased — 1 report (10%)
  6. Metastasis — 1 report (10%)
  7. Mobility Decreased — 1 report (10%)
  8. Myocardial Infarction — 1 report (10%)
  9. Pelvic Pain — 1 report (10%)
  10. Prostate Cancer — 1 report (10%)

Source database →

5-alpha reductase inhibitor in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is 5-alpha reductase inhibitor approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for 5-alpha reductase inhibitor in United States?

Ain Shams University is the originator. The local marketing authorisation holder may differ — check the official source linked above.